Latest Regulatory News

Bellavista Resources Ltd has agreed to acquire a majority stake in the high-grade Pickle Crow Gold Project in Ontario, Canada, boasting a 2.8 million ounce inferred resource at 7.2g/t gold. The company is also raising up to A$25 million to fund aggressive exploration and development.

Mamba Exploration Limited has inked a deal to acquire a majority interest in the underexplored Meeka East Gold Project in Western Australia’s prolific Murchison Goldfield, backed by a $2 million capital raise to fund early-stage exploration.

Actinogen Medical has raised approximately $17 million through a share placement and purchase plan to fund the completion of its pivotal XanaMIA Alzheimer’s trial following encouraging interim results.

FireFly Metals has agreed to sell its Ontario gold assets, including a 70% stake in the Pickle Crow Project, to Bellavista Resources for up to A$86.1 million in scrip. FireFly shareholders will receive Bellavista shares, maintaining exposure to the assets while FireFly focuses on its copper-gold ambitions.

FireFly Metals has agreed to sell its Ontario gold assets to Bellavista Resources for up to A$86.1 million in shares and performance rights, unlocking value for shareholders while focusing on its copper-gold growth strategy.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Neurotech International has secured ethics approval to launch its Beyond Harmony Phase 3 clinical trial of NTI164 for autism spectrum disorder, marking a key step toward regulatory submissions in Australia and the US.

The ASX has suspended trading in Aspermont Limited, Koba Resources, and WA Kaolin due to their failure to lodge required periodic reports on time. The suspension may be lifted if the companies submit their reports promptly.

CurveBeam AI has received the first A$4 million tranche of a planned A$10 million strategic investment from a leading Chinese orthopaedic device company, marking a significant step in its expansion into the Chinese market.

Pivotal Metals has revealed ore sorting test results at its Horden Lake project that deliver up to a 2.1 times uplift in copper grade, promising substantial cost savings and flexible development options in Quebec’s Tier 1 mining jurisdiction.